文献速递血栓与止血

基因介导的FVIIa预防治疗调节A型血友病大鼠自发性出血表型

Gene-based FVIIa prophylaxis modulates the spontaneous bleeding phenotype of hemophilia A rats.
PubMed 文献 · Blood Adv · 2019-01-01

研究利用AAV基因转移在A型血友病大鼠中持续表达大鼠FVIIa以模拟预防治疗。 naive动物91%发生出血,FVIIa低于708 ng/mL组为83%,至少708 ng/mL组为33%,高于1250 ng/mL组无出血;至少708 ng/mL可 normalize 尾静脉损伤后失血,且未观察到止血系统明显不良反应。

要点

  • A型血友病大鼠中,AAV介导的持续FVIIa表达可减少自发性出血。
  • FVIIa低于708 ng/mL组出血比例83%,至少708 ng/mL组33%,高于1250 ng/mL组无出血。
  • 至少708 ng/mL的FVIIa表达足以使尾静脉损伤后失血恢复正常。

核心结论

  • 本研究首次在FVIIa预防治疗背景下确定了循环FVIIa抗原水平与出血减少或完全消除的剂量依赖性和阈值。

研究设计与样本

  • 研究使用具有自发性出血并允许进行有足够统计效力纵向研究的A型血友病大鼠模型。
  • 通过腺相关病毒(AAV)基因转移大鼠FVIIa转基因来模拟活化凝血因子VII(FVIIa)预防治疗。

主要发现

  • 与naive A型血友病动物相比,大鼠FVIIa持续表达影响总体观察到的出血,这些出血可通过按需给予重组大鼠FVIIa解决。
  • naive动物中91%出现出血,表达低于708 ng/mL(<14 nM)大鼠FVIIa的动物中降至83%,表达至少708 ng/mL(≥14 nM)的动物中降至33%。
  • 表达高于1250 ng/mL(>25 nM)大鼠FVIIa的动物未发生出血。
  • 至少708 ng/mL的大鼠FVIIa表达足以使尾静脉损伤后失血恢复正常。
  • 持续AAV介导的大鼠FVIIa转基因表达对A型血友病大鼠的止血系统无明显不良影响。

关键数值与推荐

  • naive动物出血比例91%,FVIIa低于708 ng/mL组83%,至少708 ng/mL组33%,高于1250 ng/mL组无出血。
  • 至少708 ng/mL的大鼠FVIIa表达使尾静脉损伤后失血恢复正常。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A sizable proportion of hemophilia inhibitor patients fails immune tolerance induction and requires bypass agents for long-term bleed management. Recombinant human-activated coagulation Factor VII (rhFVIIa) is an on-demand bypass hemostatic agent for bleeds in hemophilia inhibitor patients. Prophylactic use of rhFVIIa may enable sustained hemostatic management of inhibitor patients, but the critical relationship of rhFVIIa circulating levels and clinical outcome in that setting remains unclear. To address this in vivo, we used the rat hemophilia A (HA) model that exhibits spontaneous bleeds and allows longitudinal studies with sufficient statistical power. We simulated activated Factor VII (FVIIa) prophylaxis by adeno-associated virus (AAV) gene transfer of a rat FVIIa transgene. Compared with naive HA animals, rat FVIIa continuous expression affected the overall observed bleeds, which were resolved with on-demand administration of recombinant rat FVIIa. Specifically, although 91% of naive animals exhibited bleeds, this was reduced to 83% and 33% in animals expressing less than 708 ng/mL (<14 nM) and at least 708 ng/mL (≥14 nM) rat FVIIa, respectively. No bleeds occurred in animals expressing higher than 1250 ng/mL (>25 nM). Rat FVIIa expression of at least 708 ng/mL was also sufficient to normalize the blood loss after a tail vein injury. Continuous, AAV-mediated rat FVIIa transgene expression had no apparent adverse effects in the hemostatic system of HA rats. This work establishes for the first time a dose dependency and threshold of circulating FVIIa antigen levels for reduction or complete elimination of bleeds in a setting of FVIIa-based HA prophylaxis.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Zintner SM, Small JC, Pavani G, et al. Gene-based FVIIa prophylaxis modulates the spontaneous bleeding phenotype of hemophilia A rats. Blood Adv. 2019. PMID: 30705032. doi:10.1182/bloodadvances.2018027219

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。